Table 3

Sensitivity analysis

Parameters	Value		Year 1		Year 2		Year 3
Parameters	Value		Difference scenario with vs without	%	Difference scenario with vs without	%	Difference scenario with vs without	%
Base case			−€11 558 268	−5.1%	−€29 126 373	−8.5%	−€52 361 778	−13.6%
Biosimilar shares (base case 30%/50%/80%)	SA1	40%/60%/85%	−€15 411 024	−6.8%	−€34 951 647	−10.2%	−€55 634 389	−14.5%
	SA2	50%/80%/95%	−€19 263 780	−8.5%	−€46 602 196	−13.6%	−€62 179 612	−16.2%
	SA3	55%/85%/97%	−€21 190 158	−9.3%	−€49 427 455	−14.4%	−€63 376 617	−16.5%
Reduction of bevacizumab original price and biosimilars (before and after introduction of biosimilars)	SA4	−20%	−€9 248 549	−5.1%	−€23 264 846	−8.5%	−€41 824 250	−13.6%
	SA5	−30%	−€8 093 558	−5.1%	−€20 359 450	−8.5%	−€36 601 091	−13.6%
	SA6	−40%	−€ 6 936 412	−5.1%	−€ 17 448 634	−8.5%	−€31 368 188	−13.6%
Bevacizumab original ex-factory price equal to biosimilars ex-factory prices in scenario with bevacizumab biosimilars	SA7	€262.43	−€38 527 560	−17.0%	−€58 149 947	−17.0%	−€65 336 719	−17.0%

SA, Sensitivity analysis.